ArticleOncoimmunology2025
Novel immunotheranostic FAP-inhibitor target modules for imaging and elimination of FAP-positive cells by UniCAR T-cells.
Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Preclinical evaluation of homodimeric FAPI target modules for UniCAR-mediated targeting of FAP-expressing tumor and stromal cells.Oncoimmunology · 2026Article
- The Evolution of FAP-Targeted CAR T-Cell Therapy in Solid Tumors: From Immunotherapy to Immunotheranostic Applications.International journal of molecular sciences · 2026Review
- Homomultimeric FAP Inhibitor-Based Radioligands for Cancer Theranostics: Design Principles, Structure-Function Relationships, and Preclinical Performance.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fibroblast activation protein alpha (FAPα) is overexpressed in the tumor microenvironment of most solid cancers and, in some cases, in cancer cells, making it an interesting target for theranostic applications. T-cells modified to express a chimeric antigen receptor (CAR) against FAP have recently been described. We previously established the UniCAR system, in which UniCAR T-cells can be repeatedly switched on and off via dosing with a bifunctional adaptor molecule, known as target module (TM). Here, we describe the first FAPI-based immunotheranostic UniCAR TMs (FAPI TMs), enabling both non-invasive molecular imaging and UniCAR T-cell immunotherapy. The FAPI TMs consist of the UAMC-1110 FAPI moiety, the NODA-GA chelator for copper-64 labeling, and the UniCAR epitope (E5B9). Following computational analyses, three FAPI TMs with polyethylene glycol (PEG) spacers of either four, twelve, or 24 units were synthesized. Although the three novel TMs specifically accumulate in FAP-positive tumors in xenograft mice, only the FAPI TMs with an extended spacer (PEG
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.